tbuckley/cabot-search huggingface dataset:
Callous-Unemotional Traits and Risk of Gun Carrying and Use During Crime
Authors: Emily L. Robertson, Paul J. Frick, Toni M. Walker, Emily C. Kemp, James V. Ray, Laura C. Thornton, Tina D. Wall Myers, Laurence Steinberg, Elizabeth Cauffman
Journal: American Journal of Psychiatry (2020)

With the addition of the "with limited prosocial emotions" specifier within the diagnosis of conduct disorder (DSM-5) and of conduct-dissocial disorder (ICD-11) to designate those with elevated callous-unemotional traits, the authors examined the role that callous-unemotional traits play in the risk for gun carrying and gun use during a crime in a sample at high risk for gun violence.Male juvenile offenders (N=1,215) from three regions of the United States were assessed after their first arrest and then reassessed every 6 months for 36 months and again at 48 months. Callous-unemotional traits and peer gun carrying and ownership were measured via self-report after the first arrest (i.e., baseline). Gun carrying and use of a gun during a crime were self-reported at all follow-up points.Callous-unemotional traits at baseline increased the frequency of gun carrying and the likelihood of using a gun during a crime across the subsequent 4 years after accounting for other risk factors. Furthermore, callous-unemotional traits moderated the relationship between peer gun carrying and ownership and participant gun carrying, such that only participants low on callous-unemotional traits demonstrated increased gun carrying as a function of their peers' gun carrying and ownership.This study demonstrates the importance of considering callous-unemotional traits in gun violence research both because callous-unemotional traits increase gun carrying and use in adolescents and because the traits may moderate other key risk factors. Notably, the influence of peer gun carrying and ownership may have been underestimated in past research for the majority of adolescents by not considering the moderating influence of callous-unemotional traits.
FGFR3 mutation analysis in flat urothelial hyperplasia - strong evidence for chromosome 9 deletions as the earliest genetic alterations in the development of papillary bladder cancer
Authors: Robert Stoehr, Johanna Van Oers, Christoph Adam, Simone Bertz, Ellen Zwarthoff, Dirk Zaak, Ruth Knuechel, Arndt Hartmann
Journal: Cancer Research (2006)

346  Aims: Flat urothelial hyperplasias (FUH) in patients with papillary urothelial carcinoma (pUC) frequently show genetic alterations similar to pUC, especially deletions of chromosome 9, suggesting that FUH could be the first neoplastic step in the development of pUC. FGFR3 mutations are frequent in non-invasive papillary tumors with low risk of progression and recurrence. The aim of the present study was to investigate the frequency of FGFR3 mutations and deletions of chromosomes 9p/q and 8p/q in FUH to determine the earliest genetic alteration in the development of pUC. Methods: 30 FUH and 9 consecutive or simultaneous UC were detected by 5-ALA-based photo-dynamic cystoscopy. After laser-microdissection from frozen sections, DNA was isolated and whole genome amplification (I-PEP-PCR) was done. LOH analysis was performed using 4 markers on chromosome 8p/q and 5 markers on chromosome 9p/q. FGFR3 mutations were analysed by SNaPshot analysis. Results: FGFR3 mutations were found in 7/30 FUH (23%). LOH analyses frequently revealed deletions at 9p/q (11/30; 37%) and infrequently at 8p/q (3/30; 10%). Only 2 FUH showed an FGFR3 mutation without deletions of chromosome 9. In contrast, 6 FUH revealed chromosome 9 deletions but wild-type FGFR3 (p=0.03). Conclusions: FGFR3 mutations can be detected in FUH of patients with UC, further supporting the role of this lesion as precursor of pUC. Chromosome 9 deletions occur earlier than FGFR3 mutations in most instances and are the earliest known genetic alteration in bladder cancer.
Fosfomycin as a potential treatment for neonatal sepsis An open label randomised clinical trial evaluating safety and pharmacokinetics
Authors: C Obiero, P Williams, S Murunga, J Thitiri, R Omollo, A S Walker, T Egondi, B Nyoake, E Correia, Z Kane, S Gastine, K Kipper, J Standing, S Ellis, M Sharland, J Berkley
Journal: The Lancet Infectious Diseases (2020)
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
Authors: Eric Lawitz, Charles S Landis, Steven L Flamm, Maurizio Bonacini, Grisell Ortiz-Lasanta, Jonathan Huang, Jie Zhang, Brian J Kirby, Shampa De-Oertel, Robert H Hyland, Anu O Osinusi, Diana M Brainard, Richard Robson, Benedict J Maliakkal, Stuart C Gordon, Edward J Gane
Journal: The Lancet. Gastroenterology & hepatology (2020)
TH cell diversity and response to dupilumab in patients with atopic dermatitis
Authors: Coline Trichot, Lilith Faucheux, Léa Karpf, Maximilien Grandclaudon, Lucia Pattarini, Martine Bagot, Thibault Mahévas, Marie Jachiet, Anne Saussine, Jean-David Bouaziz, Vassili Soumelis
Journal: Journal of Allergy and Clinical Immunology (2020)
The effectiveness of rituximab in pemphigus and the benefit of additional maintenance infusions: Daily practice data from a retrospective study
Authors: Hanan Rashid, Aniek Lamberts, Dian van Maanen, Maria C. Bolling, Gilles F.H. Diercks, Hendri H. Pas, Marcel F. Jonkman, Barbara Horváth
Journal: Journal of the American Academy of Dermatology (2020)
FRI0537 INTERSTITIAL LUNG DISEASE IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME—AN OVERVIEW OF CLINICAL CHARACTERISTICS AND TREATMENT IN A TERTIARY CENTER IN TAIWAN
Authors: H. T. Huang
Journal: Annals of the Rheumatic Diseases (2020)

Background: Interstitial lung disease(ILD) is one of the major contributor to morbidity and mortality in primary Sjögren’s syndrome(pSS) 1 . However, the clinical features and prognosis were various in literatures 1-3 ; and the optimal management were still under investigation Objectives: To characterize the clinical feature, treatment and prognosis predictor of ILD of pSS in a tertiary medical center in Taiwan. Methods: Patients who had pSS and ILD confirmed with HRCT of lung between 1999-2019 were retrospectively identified. Demographic data, autoimmune feature, complementary examinations and treatments were recorded. Change in pulmonary function tests compared with pre-rituximab or pre-cyclophosphamide levels was assessed at 6–12 months post-treatment. Secondary analyses included acute exacerbation(AE), infection, and survival between different treatment groups. Results: 112 patients (mean age 68(56-80); 67% female) were analyzed with the median pSS duration 3.1 (0.8-8.0) years. Most patients presented dyspnea and cough. NSIP was the most common radiological pattern (42.9%), followed by UIP (31.3%). Rituximab was used in 11(9.8%) patients, cyclophosphamide(CYC) was used in 28(25%) patients, and combination was used in 20(17.9%) patients. The FVC level and DLCO% were stable after 6-12month post-treatment in these groups. During the median 3.4(1.3-7.7) years ILD follow up, 88 patients (78.6%) had been hospitalized because of AE or infection; with 34(30.4%) of them experiencing respiratory failure. 1-year and 5-year survival was 88.6% and 67.1%. No significant overall survival was distinguished between different treatment groups(p=0.36). Frequent AE (HR=2.17, 95% CI: 1.36-3.5) and respiratory failure (HR=29, 95% CI: 4.61-191) contributed to mortality, while UIP pattern did not (HR=1.6, 95% CI: 0.77-3.3). Figure 1. Kaplan-Meier survival plot of different treatment group: R, E+R, E Conclusion: Rituximab or CYC may stabilize pulmonary function but may not benefit on overall survival. Frequent ILD AE and respiratory failure are risk factors of mortality in pSS-ILD. References: [1] McCoy SS, Sandbo N. Sjögren’s Syndrome-Associated Lung Disease. Clinical Pulmonary Medicine. 2017;24(6):232-238. [2] Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH. Interstitial Lung Disease in Primary Sjögren Syndrome. Chest. 2006;130(5):1489-1495. [3] Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren’s syndrome. European Respiratory Review. 2016;25:110-123. Acknowledgments: Thanks to Dr. Ting-Yuan Lan, Dr. Ko-Jen Li, Dr. Hsieh Song-Chou, Dr. I-Hsien Lee, Dr. Chen-Yen Lin, Dr. Wang Hao Chien Disclosure of Interests: None declared
Measuring the effectiveness of an automated text messaging active surveillance system for COVID-19 in the south of Ireland, March to April 2020
Authors: Peter M Barrett, Niamh Bambury, Louise Kelly, Rosalind Condon, Janice Crompton, Anne Sheahan
Journal: Eurosurveillance (2020)

We report the effectiveness of automated text messaging for active surveillance of asymptomatic close contacts of coronavirus disease (COVID-19) cases in the Cork/Kerry region of Ireland. In the first 7 weeks of the COVID-19 outbreak, 1,336 close contacts received 12,421 automated texts. Overall, 120 contacts (9.0%) reported symptoms which required referral for testing and 35 (2.6%) tested positive for COVID-19. Non-response was high (n = 2,121; 17.1%) and this required substantial clinical and administrative resources for follow-up.
A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2
Authors: Carmen Riggioni, Pasquale Comberiati, Mattia Giovannini, Ioana Agache, Mübeccel Akdis, Magna Alves‐Correia, Josep M. Antó, Alessandra Arcolaci, Ahmet Kursat Azkur, Dilek Azkur, Burcin Beken, Cristina Boccabella, Jean Bousquet, Heimo Breiteneder, Daniela Carvalho, Leticia De las Vecillas, Zuzana Diamant, Ibon Eguiluz‐Gracia, Thomas Eiwegger, Stefanie Eyerich, Wytske Fokkens, Ya‐dong Gao, Farah Hannachi, Sebastian L. Johnston, Marek Jutel, Aspasia Karavelia, Ludger Klimek, Beatriz Moya, Kari C. Nadeau, Robyn O'Hehir, Liam O'Mahony, Oliver Pfaar, Marek Sanak, Jürgen Schwarze, Milena Sokolowska, María J. Torres, Willem van de Veen, Menno C. van Zelm, De Yun Wang, Luo Zhang, Rodrigo Jiménez‐Saiz, Cezmi A. Akdis
Journal: Allergy (2020)

Abstract In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome–related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19–related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease.
Indoxyl sulfate induces intestinal barrier injury through IRF1-DRP1 axis-mediated mitophagy impairment
Authors: Yinghui Huang, Jie Zhou, Shaobo Wang, Jiachuan Xiong, Yin Chen, Yong Liu, Tangli Xiao, Yi Li, Ting He, Yan Li, Xianjin Bi, Ke Yang, Wenhao Han, Yu Qiao, Yanli Yu, Jinghong Zhao
Journal: Theranostics (2020)

Rationale:The dysfunctional gut-kidney axis forms a vicious circle, which eventually becomes a catalyst for the progression of chronic kidney disease (CKD) and occurrence of related complications.However, the pathogenic factors of CKD-associated intestinal dysfunction and its mechanism remain elusive.Methods: We first identified the protein-bound uremic toxin indoxyl sulfate (IS) as a possible contributor to intestinal barrier injury.Transepithelial electrical resistance, permeability assay and transmission electron microscopy were carried out to evaluate the damaging effect of IS on intestinal barrier in intestinal epithelial cells, IS-injected mice and CKD mice.In vitro and in vivo experiments were performed to investigate the role of IS in intestinal barrier injury and the underlying mechanism.Finally, CKD mice treated with AST-120 (an oral adsorbent for IS) and gene knockout mice were used to verify the mechanism and to explore possible interventions for IS-induced intestinal barrier injury.Results: Transepithelial electrical resistance and the expressions of tight junction-related genes were significantly suppressed by IS in intestinal epithelial cells.In vitro experiments demonstrated that IS inhibited the expression of dynamin-related protein 1 (DRP1) and mitophagic flux, whereas DRP1 overexpression attenuated IS-induced mitophagic inhibition and intestinal epithelial cell damage.Furthermore, IS suppressed DRP1 by upregulating the expression of interferon regulatory factor 1 (IRF1), and IRF1 could directly bind to the promoter region of DRP1.Additionally, the decreased expression of DRP1 and autophagosome-encapsulated mitochondria were observed in the intestinal tissues of CKD patients.Administration of AST-120 or genetic knockout of IRF1 attenuated IS-induced DRP1 reduction, mitophagic impairment and intestinal barrier injury in mice.Conclusions: These findings suggest that reducing IS accumulation or targeting the IRF1-DRP1 axis may be a promising therapeutic strategy for alleviating CKD-associated intestinal dysfunction.
Abstract 19490: National Trends of Diagnostic Right Heart Catheterization in the United States
Authors: Manyoo Agarwal, Brijesh Patel, Mahek Shah, Sahil Agrawal, Lohit Garg, Rami N Khouzam
Journal: Circulation (2017)

Introduction: While recent studies have shown declining trends for bedside pulmonary artery catheterization (PAC) use, data describing diagnostic right heart catheterization (RHC) is lacking. Hypot...
Acute Start Peritoneal Dialysis during the COVID-19 Pandemic: Outcomes and Experiences
Authors: Osama El Shamy, Niralee Patel, Mohamed Halim Abdelbaset, Linda Chenet, Joji Tokita, Robert Lookstein, David S. Lee, Noah A. Cohen, Shuchita Sharma, Jaime Uribarri
Journal: Journal of the American Society of Nephrology (2020)

Hospitalized patients with AKI rarely initiate peritoneal dialysis (PD) because of the limited availability of surgeons or interventionists with experience in placing PD catheters as well as of nephrologists and trained nursing staff who can manage and perform PD. Moreover, to minimize the incidence
Establishment, Characterization, and Imaging of a First Platinum-resistant Penile Cancer Patient-derived Xenograft in Nude Mice: A eUROGEN Project
Authors: Anita Thomas, Joren Vanthoor, Uwe Himmelreich, Christopher Cawthorne, Christophe M. Deroose, Willy Gsell, Lien Spans, Lara Rizzotto, Eleonora Leucci, Anne-Sophie Van Rompuy, Asif Muneer, Maarten Albersen
Journal: European Urology (2020)
Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Erik Ladomersky, Lijie Zhai, Kristen L. Lauing, April Bell, Jiahui Xu, Masha Kocherginsky, Bin Zhang, Jennifer D. Wu, Joseph R. Podojil, Leonidas C. Platanias, Aaron Y. Mochizuki, Robert M. Prins, Priya Kumthekar, Jeffrey J. Raizer, Karan Dixit, Rimas V. Lukas, Craig Horbinski, Min Wei, Changyou Zhou, Graham Pawelec, Judith Campisi, Ursula Grohmann, George C. Prendergast, David H. Munn, Derek A. Wainwright
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Wild-type isocitrate dehydrogenase–expressing glioblastoma (GBM) is the most common and aggressive primary brain tumor with a median age at diagnosis of ≥65 years. It accounts for approximately 90% of all GBMs and has a median overall survival (OS) of &amp;lt;15 months. Although immune checkpoint blockade (ICB) therapy has achieved remarkable survival benefits in a variety of aggressive malignancies, similar success has yet to be achieved for GBM among phase III clinical trials to date. Our study aimed to understand the relationship between subject age and immunotherapeutic efficacy as it relates to survival from glioma. Experimental Design: (i) Clinical data: GBM patient datasets from The Cancer Genome Atlas, Northwestern Medicine Enterprise Data Warehouse, and clinical studies evaluating ICB were stratified by age and compared for OS. (ii) Animal models: young, middle-aged, and older adult wild-type and indoleamine 2,3 dioxygenase (IDO)-knockout syngeneic mice were intracranially engrafted with CT-2A or GL261 glioma cell lines and treated with or without CTLA-4/PD-L1 mAbs, or radiation, anti–PD-1 mAb, and/or a pharmacologic IDO enzyme inhibitor. Results: Advanced age was associated with decreased GBM patient survival regardless of treatment with ICB. The advanced age–associated increase of brain IDO expression was linked to the suppression of immunotherapeutic efficacy and was not reversed by IDO enzyme inhibitor treatment. Conclusions: Immunosuppression increases in the brain during advanced age and inhibits antiglioma immunity in older adults. Going forward, it will be important to fully understand the factors and mechanisms in the elderly brain that contribute to the decreased survival of older patients with GBM during treatment with ICB.
In vitro platform establishes antigen-specific CD8+ T cell cytotoxicity to encapsulated cells via indirect antigen recognition
Authors: Ying Li, Anthony W. Frei, Ethan Y. Yang, Irayme Labrada-Miravet, Chuqiao Sun, Yanan Rong, Magdalena M. Samojlik, Allison L. Bayer, Cherie L. Stabler
Journal: Biomaterials (2020)
Abstract 12582: Is Lipid Lowering Therapy Being Intensified in the United States?: Primary, One-year Results of the Getting to an Improved Understanding of Low-density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) Registry of Patients With Atherosclerotic Cardiovascular Disease (ASCVD)
Authors: Christopher P Cannon, James A De Lemos, Christie M Ballantyne, Robert S Rosenson, Shushama Alam, Mary Elliott-Davey, Katie Mues, Yuyin Liu, Deepak L Bhatt, Mikhail N Kosiborod
Journal: Circulation (2019)

Introduction: Atherosclerotic cardiovascular disease (ASCVD) treatment guidelines recommend intensive statin therapy and adding non-statin therapy if LDL-C >70 mg/dL. Methods: We designed the GOULD...
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series
Authors: Ivan Fan-Ngai Hung, Vincent Chi-Chung Cheng, Xin Li, Anthony Raymond Tam, Derek Ling-Lung Hung, Kelvin Hei-Yeung Chiu, Cyril Chik-Yan Yip, Jian-Piao Cai, Deborah Tip-Yin Ho, Shuk-Ching Wong, Sally Sau-Man Leung, Man-Yee Chu, Milky Oi-Yan Tang, Jonathan Hon-Kwan Chen, Rosana Wing-Shan Poon, Agnes Yim-Fong Fung, Ricky Ruiqi Zhang, Erica Yuen-Wing Yan, Lin-Lei Chen, Charlotte Yee-Ki Choi, Kit-Hang Leung, Tom Wai-Hin Chung, Sonia Hiu-Yin Lam, Tina Poy-Wing Lam, Jasper Fuk-Woo Chan, Kwok-Hung Chan, Tak-Chiu Wu, Pak-Leung Ho, Johnny Wai-Man Chan, Chak-Sing Lau, Kelvin Kai-Wang To, Kwok-Yung Yuen
Journal: The Lancet Infectious Diseases (2020)
SWISS: multiplexed orthogonal genome editing in plants with a Cas9 nickase and engineered CRISPR RNA scaffolds
Authors: Chao Li, Yuan Zong, Shuai Jin, Haocheng Zhu, Dexing Lin, Shengnan Li, Jin-Long Qiu, Yanpeng Wang, Caixia Gao
Journal: Genome biology (2020)

Abstract We describe here a CRISPR simultaneous and wide-editing induced by a single system (SWISS), in which RNA aptamers engineered in crRNA scaffold recruit their cognate binding proteins fused with cytidine deaminase and adenosine deaminase to Cas9 nickase target sites to generate multiplexed base editing. By using paired sgRNAs, SWISS can produce insertions/deletions in addition to base editing. Rice mutants are generated using the SWISS system with efficiencies of cytosine conversion of 25.5%, adenine conversion of 16.4%, indels of 52.7%, and simultaneous triple mutations of 7.3%. The SWISS system provides a powerful tool for multi-functional genome editing in plants.
Green endoscopy: a call for sustainability in the midst of COVID-19
Authors: James B Maurice, Keith Siau, Shaji Sebastian, Nitin Ahuja, Emma Wesley, William Stableforth, Bu'Hussain Hayee
Journal: The Lancet. Gastroenterology & hepatology (2020)

The coronavirus disease 2019 (COVID-19) pandemic has led to radical curtailing and reconfiguring of health services across the world to slow the spread of the disease. Planning for acute COVID-19 services has inevitably resulted in a precipitous reduction in endoscopy activity, but in the deceleration phase of the pandemic, endoscopy units will aim to restart. The primary concern will understandably be to protect patients and staff, while providing enough capacity to meet demand and manage postponed appointments.
In MRSA bacteremia, adding a β-lactam to usual care did not improve a composite outcome at 90 days
Authors: Eleftheria Atalla, Eleftherios Mylonakis
Journal: Annals of Internal Medicine (2020)

Source Citation Tong SY, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323:527-37. 32044943
Acid‐Induced In Vivo Assembly of Gold Nanoparticles for Enhanced Photoacoustic Imaging‐Guided Photothermal Therapy of Tumors
Authors: Ruili Zhang, Linlin Wang, Xiaofei Wang, Qian Jia, Zhuang Chen, Zuo Yang, Renchuan Ji, Jie Tian, Zhongliang Wang
Journal: Advanced Healthcare Materials (2020)

The complexity of biological systems poses a great challenge in the development of nanotheranostic agents with enhanced therapeutic efficacies. To systematically overcome a series of barriers during in vivo administration and achieve optimal antitumor activity, nanotheranostic agents that can self-adaptively change their properties in response to certain tumor-associated signals are highly preferable. Herein, gold nanoparticles with a mixed-charge zwitterionic surface (Au-MUA-TMA) is fabricated, which can undergo pH-triggered self-assembly for promoting tumor targeting and improving photoacoustic imaging (PAI)-guided photothermal tumor ablation. In blood and normal tissues, relatively small-sized Au-MUA-TMA can circulate stably, and upon arriving at the tumor sites, they quickly assemble into larger aggregates in an acidic tumor environment to ensure higher tumor accumulation and retention. Furthermore, the absorption band of Au-MUA-TMA can be remarkably shifted to the near-infrared (NIR) region, which effectively activates the photoacoustic (PA) signals of tumors and enhances photothermal therapy (PTT) with minimal side effects. This in vivo self-assembly strategy enables the nanotheranostic agents to better fulfill multiple requirements for in vivo application, thereby attaining advanced performances in cancer diagnosis and treatment.
Guanylate-binding proteins convert cytosolic bacteria into caspase-4 signaling platforms
Authors: Michal P. Wandel, Bae-Hoon Kim, Eui-Soon Park, Keith B. Boyle, Komal Nayak, Brice Lagrange, Adrian Herod, Thomas Henry, Matthias Zilbauer, John Rohde, John D. MacMicking, Felix Randow
Journal: Nature Immunology (2020)